Physician profile
Mark C Stine
NPI 1174563449
$3,641.92
in general payments reported to CMS, 2019-2025
23 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $186 · 2021: $376 · 2022: $495 · 2023: $1,039 · 2024: $747 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,245.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $776.31 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $468.07 | 2019-2025 | Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $429.75 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $350.29 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $265.76 | 2020-2025 | |
| Glaxosmithkline, LLC. | $249.71 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $247.19 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $203.88 | 2020-2024 | Xarelto |
| Abbott Laboratories | $117.19 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Tetraphase Pharmaceuticals, INC. | $107.45 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.91 | 2023 | |
| Astellas Pharma US INC | $77.92 | 2024-2025 | Veozah |
| Esperion Therapeutics, INC. | $60.56 | 2021 | |
| Idorsia Pharmaceuticals US INC | $40.44 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.24 | 2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $21.98 | 2019 | |
| Eisai INC. | $18.01 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.39 | 2020 | |
| Boston Scientific Corporation | $15.81 | 2023 | Watchman Access System |
| Amgen INC. | $15.39 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.60 | 2022 | |
| Ibsa Pharma INC. | $13.99 | 2019 | |
| Allergan, INC. | $13.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.